Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241906704> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4241906704 endingPage "618" @default.
- W4241906704 startingPage "618" @default.
- W4241906704 abstract "618 Background: MGN1703 is a synthetic DNA-based immunomodulator, which acts as an agonist of toll-like receptor 9. The antineoplastic activity of MGN1703 was previously shown in several in-vitro and in-vivo models. A good safety profile of MGN1703 was shown in regulatory required acute and chronic toxicity studies. A currently finished phase I study in patients with metastatic solid tumors including those with CRC provided evidence for a favorable safety profile of the investigational drug as well as demonstrated positive preliminary efficacy results. Based on these promising data, a phase II/III study was initiated in patients with advanced CRC. Methods: This international multicentric randomized placebo-controlled phase II/III clinical study is being conducted in patients with advanced CRC with disease control after first-line induction therapy with standard chemotherapy regimen in combination with bevacizumab. One hundred and twenty nine patients have to be recruited to the study and randomized to be treated ether with MGN1703 or with placebo (with a ratio of 2:1), respectively. The recruited patients are treated twice a week with subcutaneous administration of 60 mg MGN1703. This dose has been proven to be safe in the phase I clinical study. The efficacy and safety of the study treatment will be evaluated based on extensive immunological tests, radiological assessment, safety laboratory results and assessments of the quality of life. The study treatment will be continued up to occurrence of tumor progression, intolerable toxicity, exclusion criteria, and withdrawal of consent or death. [Table: see text]" @default.
- W4241906704 created "2022-05-12" @default.
- W4241906704 creator A5002926775 @default.
- W4241906704 creator A5013159718 @default.
- W4241906704 creator A5026754394 @default.
- W4241906704 creator A5043002214 @default.
- W4241906704 creator A5044719324 @default.
- W4241906704 creator A5083003065 @default.
- W4241906704 creator A5083036547 @default.
- W4241906704 date "2011-02-01" @default.
- W4241906704 modified "2023-09-25" @default.
- W4241906704 title "Preliminary results of an ongoing phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line induction therapy (IMPACT Study)." @default.
- W4241906704 doi "https://doi.org/10.1200/jco.2011.29.4_suppl.618" @default.
- W4241906704 hasPublicationYear "2011" @default.
- W4241906704 type Work @default.
- W4241906704 citedByCount "1" @default.
- W4241906704 countsByYear W42419067042015 @default.
- W4241906704 crossrefType "journal-article" @default.
- W4241906704 hasAuthorship W4241906704A5002926775 @default.
- W4241906704 hasAuthorship W4241906704A5013159718 @default.
- W4241906704 hasAuthorship W4241906704A5026754394 @default.
- W4241906704 hasAuthorship W4241906704A5043002214 @default.
- W4241906704 hasAuthorship W4241906704A5044719324 @default.
- W4241906704 hasAuthorship W4241906704A5083003065 @default.
- W4241906704 hasAuthorship W4241906704A5083036547 @default.
- W4241906704 hasConcept C121608353 @default.
- W4241906704 hasConcept C126322002 @default.
- W4241906704 hasConcept C141071460 @default.
- W4241906704 hasConcept C142724271 @default.
- W4241906704 hasConcept C143998085 @default.
- W4241906704 hasConcept C203092338 @default.
- W4241906704 hasConcept C204787440 @default.
- W4241906704 hasConcept C27081682 @default.
- W4241906704 hasConcept C2776694085 @default.
- W4241906704 hasConcept C2777802072 @default.
- W4241906704 hasConcept C2781413609 @default.
- W4241906704 hasConcept C29730261 @default.
- W4241906704 hasConcept C31760486 @default.
- W4241906704 hasConcept C526805850 @default.
- W4241906704 hasConcept C535046627 @default.
- W4241906704 hasConcept C71924100 @default.
- W4241906704 hasConcept C90924648 @default.
- W4241906704 hasConceptScore W4241906704C121608353 @default.
- W4241906704 hasConceptScore W4241906704C126322002 @default.
- W4241906704 hasConceptScore W4241906704C141071460 @default.
- W4241906704 hasConceptScore W4241906704C142724271 @default.
- W4241906704 hasConceptScore W4241906704C143998085 @default.
- W4241906704 hasConceptScore W4241906704C203092338 @default.
- W4241906704 hasConceptScore W4241906704C204787440 @default.
- W4241906704 hasConceptScore W4241906704C27081682 @default.
- W4241906704 hasConceptScore W4241906704C2776694085 @default.
- W4241906704 hasConceptScore W4241906704C2777802072 @default.
- W4241906704 hasConceptScore W4241906704C2781413609 @default.
- W4241906704 hasConceptScore W4241906704C29730261 @default.
- W4241906704 hasConceptScore W4241906704C31760486 @default.
- W4241906704 hasConceptScore W4241906704C526805850 @default.
- W4241906704 hasConceptScore W4241906704C535046627 @default.
- W4241906704 hasConceptScore W4241906704C71924100 @default.
- W4241906704 hasConceptScore W4241906704C90924648 @default.
- W4241906704 hasIssue "4_suppl" @default.
- W4241906704 hasLocation W42419067041 @default.
- W4241906704 hasOpenAccess W4241906704 @default.
- W4241906704 hasPrimaryLocation W42419067041 @default.
- W4241906704 hasRelatedWork W1051628 @default.
- W4241906704 hasRelatedWork W12229326 @default.
- W4241906704 hasRelatedWork W19039903 @default.
- W4241906704 hasRelatedWork W21299109 @default.
- W4241906704 hasRelatedWork W317545 @default.
- W4241906704 hasRelatedWork W4112738 @default.
- W4241906704 hasRelatedWork W4429043 @default.
- W4241906704 hasRelatedWork W5346711 @default.
- W4241906704 hasRelatedWork W6531846 @default.
- W4241906704 hasRelatedWork W18345989 @default.
- W4241906704 hasVolume "29" @default.
- W4241906704 isParatext "false" @default.
- W4241906704 isRetracted "false" @default.
- W4241906704 workType "article" @default.